Ottobock SE & Co. KGaA, the listed global MedTech company, has announced the appointment of Dr. Katarzyna Mazur-Hofsaess to its Management Board, effective June 22, 2026. She succeeds Stefan Heidenreich, whose regular five-year term on the Management Board has concluded.
Dr. Mazur-Hofsaess brings extensive international experience in medical technology and healthcare to her new role. From 2018 to 2025, she served on the Management Board of Fresenius Medical Care and as CEO of the company's MedTech segment, Care Enablement. Prior to that, she was responsible for the EMEA region at Zimmer Biomet, a US-based specialist in joint replacement solutions. Earlier in her career, she held positions at Abbott Diagnostics and Roche Polska. She is also currently active as an independent, non-executive Director at Smith & Nephew.
A physician by training, Dr. Mazur-Hofsaess earned her doctorate at the Medical University of Gdansk and completed management studies at the Warsaw School of Economics and the University of Minnesota. She began her professional career at the University Clinical Centre in Gdansk.
Professor Hans Georg Nader, Chairman of the Management Board of Ottobock, commented, "With Dr. Katarzyna Mazur-Hofsaess, we are gaining a proven expert in international medical technology and healthcare. Her experience in global companies and her medical background will be a valuable addition to our Board."
Stefan Heidenreich is stepping down after a regular five-year term, during which he served as Deputy Chairman of the Management Board and played a key role in shaping the company's strategic development. Ottobock expressly thanked him for his contributions to the company's evolution into a listed entity.
This leadership change comes as the MedTech industry continues to evolve rapidly, with increasing demand for innovative solutions in prosthetics, orthotics, and exoskeletons. Ottobock, which operates in 45 countries with nearly 9,300 employees and around 420 patient care centers worldwide, is a key player in the field. The company holds more than 2,600 patents and patent applications and is known for its strong R&D focus. Dr. Mazur-Hofsaess's appointment is expected to further strengthen Ottobock's strategic direction, particularly in digitalization and global expansion.
Ottobock's mission to improve people's freedom of movement, quality of life, and independence is central to its operations. The company has been a partner and supporter of the Paralympic Games since 1988, reflecting its commitment to social responsibility. With the addition of Dr. Mazur-Hofsaess, the company aims to continue its trajectory of growth and innovation in the MedTech sector.
For more information, the original press release is available at www.newmediawire.com.
